Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Study ID
- NCT05063110
- Phase
- PHASE2
- Status
- Completed
Conditions
- Adults Patients Having Non Severe HLH
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Itacitinib — DRUGAdministration of 300 mg of ITACITINIB per os every day for 30 days.
Study Details
This project aims to test the effectiveness of ITACITINIB in sporadic Hemophagocytosis Lymphohistiocytosis (HLHs)
Key Dates
- Start date
- May 3, 2022
- Status verified
- Oct 2025
- Primary completion
- Apr 3, 2025
- Completion
- Oct 1, 2025
Study Design
- Enrollment
- 35 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment arm300 mg of ITACITINIB will be administrated per os every day for 30 days, dose with reduction to 200 mg per safety is allowed if AEs are observed or if co-administered a strong CYP3A inhibitor
Primary Outcome Measure
Efficacy of ITACITINIB [ Time Frame: At day 15 ]